Hemodynamic changes in neonates born to mothers with Graves' disease.
Cardiac output
Echocardiography
N-terminal-pro-B-type natriuretic peptide
Neonatal hyperthyroidism
Thyroid-stimulating hormone receptor antibody
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
12
04
2020
accepted:
28
07
2020
pubmed:
14
8
2020
medline:
9
7
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Cardiac insufficiency is a major morbidity in neonatal hyperthyroidism. It is important to assess the hemodynamics in neonates born to mothers with Graves' disease (GD). This study prospectively evaluated the hemodynamic changes in neonates born to mothers with GD. Overall, 80 newborns were enrolled. Thirty-six neonates were born to mothers with GD who were positive for thyroid-stimulating hormone (TSH) receptor antibody (TRAb), and 44 were born to mother negative for TRAb. The serum levels of TSH, free triiodothyronine (FT The TRAb-positive newborns had higher FT Hemodynamic changes in neonates born to TRAb-positive mothers with GD resulted in a higher CI and NT-proBNP levels than in those with TRAb-negative mothers from postnatal days 5 to 10.
Identifiants
pubmed: 32785898
doi: 10.1007/s12020-020-02443-w
pii: 10.1007/s12020-020-02443-w
doi:
Substances chimiques
Triiodothyronine
06LU7C9H1V
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-178Références
P. Sunshine, H. Kusumoto, J.P. Kriss, Survival time of circulating long-acting thyroid stimulator in neonatal thyrotoxicosis: implications for diagnosis and therapy of the disorder. Pediatrics 36(6), 869–876 (1965)
pubmed: 5846829
J.M. McKenzie, M. Zakarija, Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 2(2), 155–159 (1992). https://doi.org/10.1089/thy.1992.2.155
doi: 10.1089/thy.1992.2.155
pubmed: 1356056
P. Laurberg, C. Bournaud, J. Karmisholt, J. Orgiazzi, Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur. J. Endocrinol. 160(1), 1–8 (2009). https://doi.org/10.1530/eje-08-0663
doi: 10.1530/eje-08-0663
pubmed: 18849306
D. Zimmerman, Fetal and neonatal hyperthyroidism. Thyroid 9(7), 727–733 (1999). https://doi.org/10.1089/thy.1999.9.727
doi: 10.1089/thy.1999.9.727
pubmed: 10447021
M. Polak, Hyperthyroidism in early infancy: pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Thyroid 8(12), 1171–1177 (1998). https://doi.org/10.1089/thy.1998.8.1171
doi: 10.1089/thy.1998.8.1171
pubmed: 9920374
G. Radetti, A. Zavallone, L. Gentili, P. Beck-Peccoz, G. Bona, Foetal and neonatal thyroid disorders. Minerva Pediatr. 54(5), 383–400 (2002)
pubmed: 12244277
E.S. Lightner, H.D. Allen, G. Loughlin, Neonatal hyperthyroidism and heart failure. A differential approach. Am. J. Dis. Child. 131(1), 68–70 (1977). https://doi.org/10.1001/archpedi.1977.02120140070012
doi: 10.1001/archpedi.1977.02120140070012
pubmed: 576368
Y.L. Bussmann, M.L. Tillman, A.S. Pagliara, Neonatal thyrotoxicosis associated with the hyperviscosity syndrome. J. Pediatr. 90(2), 266–268 (1977). https://doi.org/10.1016/s0022-3476(77)80648-3
doi: 10.1016/s0022-3476(77)80648-3
pubmed: 830919
D. O’Donovan, C. McMahon, C. Costigan, P. Oslizlok, D. Duff, Reversible pulmonary hypertension in neonatal Graves disease. Ir. Med. J. 90(4), 147–148 (1997)
pubmed: 9267095
A.A. Zuppa, P. Sindico, I. Savarese, V. D’Andrea, A. Fracchiolla, F. Cota, C. Romagnoli, Neonatal hyperthyroidism: neonatal clinical course of two brothers born to a mother with Graves-Basedow disease, before and after total thyroidectomy. J. Pediatr. Endocrinol. Metab. 20(4), 535–539 (2007). https://doi.org/10.1515/jpem.2007.20.4.535
doi: 10.1515/jpem.2007.20.4.535
pubmed: 17550218
L.Q. Gu, L. Zhao, W. Zhu, F.Y. Li, M.J. Zhang, Y. Liu, J.M. Liu, G. Ning, Y.J. Zhao, Relationships between serum levels of thyroid hormones and serum concentrations of asymmetric dimethylarginine (ADMA) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patients with Graves’ disease. Endocrine. 39(3), 266–271 (2011). https://doi.org/10.1007/s12020-011-9436-7
doi: 10.1007/s12020-011-9436-7
pubmed: 21387129
S. Arikan, A. Tuzcu, D. Gokalp, M. Bahceci, R. Danis, Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction. Clin. Endocrinol. 67(2), 202–207 (2007). https://doi.org/10.1111/j.1365-2265.2007.02861.x
doi: 10.1111/j.1365-2265.2007.02861.x
B. Ozmen, D. Ozmen, Z. Parildar, I. Mutaf, O. Bayindir, Serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr. Res. 32(1-2), 1–8 (2007). https://doi.org/10.1080/07435800701670047
doi: 10.1080/07435800701670047
pubmed: 18271501
C. Massart, J. Orgiazzi, D. Maugendre, Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves’ disease treated with antithyroid drugs. Clin. Chim. Acta. 304(1–2), 39–47 (2001). https://doi.org/10.1016/s0009-8981(00)00385-5
doi: 10.1016/s0009-8981(00)00385-5
pubmed: 11165197
A.P. Weetman, Graves’ disease. N. Engl. J. Med. 343(17), 1236–1248 (2000). https://doi.org/10.1056/nejm200010263431707
doi: 10.1056/nejm200010263431707
pubmed: 11071676
E. Lechner, G. Wiesinger-Eidenberger, O. Wagner, M. Weissensteiner, E. Schreier-Lechner, D. Leibetseder, W. Arzt, G. Tulzer, Amino terminal pro B-type natriuretic peptide levels are elevated in the cord blood of neonates with congenital heart defect. Pediatr. Res. 66(4), 466–469 (2009). https://doi.org/10.1203/PDR.0b013e3181b3aee4
doi: 10.1203/PDR.0b013e3181b3aee4
pubmed: 19581836
I. Farombi-Oghuvbu, T. Matthews, P.D. Mayne, H. Guerin, J.D. Corcoran, N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch. Dis. Child. Fetal. Neonatal. Ed. 93(4), F257–F260 (2008). https://doi.org/10.1136/adc.2007.120691
doi: 10.1136/adc.2007.120691
pubmed: 18218660
E.W. Reynolds, J.G. Ellington, M. Vranicar, H.S. Bada, Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 114(5), 1297–1304 (2004). https://doi.org/10.1542/peds.2004-0525
doi: 10.1542/peds.2004-0525
pubmed: 15520111
van der Kaay D. C., Wasserman J. D., Palmert M. R. Management of neonates born to mothers with Graves’ disease. Pediatrics 137(4) (2016). https://doi.org/10.1542/peds.2015-1878
T. Tajima, W. Jo, K. Fujikura, M. Fukushi, K. Fujieda, Elevated free thyroxine levels detected by a neonatal screening system. Pediatr. Res. 66(3), 312–316 (2009). https://doi.org/10.1203/PDR.0b013e3181b1bcbd
doi: 10.1203/PDR.0b013e3181b1bcbd
pubmed: 19542904
L. Schwachtgen, M. Herrmann, T. Georg, P. Schwarz, N. Marx, A. Lindinger, Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z. Kardiol. 94(6), 399–404 (2005). https://doi.org/10.1007/s00392-005-0246-x
doi: 10.1007/s00392-005-0246-x
pubmed: 15940440
N. Mitsuda, H. Tamaki, N. Amino, T. Hosono, K. Miyai, O. Tanizawa, Risk factors for developmental disorders in infants born to women with Graves disease. Obstet. Gynecol. 80(3 Pt 1), 359–364 (1992)
pubmed: 1379702
M.J. Kempers, D.A. van Tijn, A.S. van Trotsenburg, J.J. de Vijlder, B.M. Wiedijk, T. Vulsma, Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. J. Clin. Endocrinol. Metab. 88(12), 5851–5857 (2003). https://doi.org/10.1210/jc.2003-030665
doi: 10.1210/jc.2003-030665
pubmed: 14671180
L.E. Teichholz, T. Kreulen, M.V. Herman, R. Gorlin, Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am. J. Cardiol. 37(1), 7–11 (1976). https://doi.org/10.1016/0002-9149(76)90491-4
doi: 10.1016/0002-9149(76)90491-4
pubmed: 1244736
M. Zakarija, J.M. McKenzie, W.H. Hoffman, Prediction and therapy of intrauterine and late-onset neonatal hyperthyroidism. J. Clin. Endocrinol. Metab. 62(2), 368–371 (1986). https://doi.org/10.1210/jcem-62-2-368
doi: 10.1210/jcem-62-2-368
pubmed: 2867106
M. Schultz, C. Kistorp, B. Langdahl, I. Raymond, P. Hildebrandt, J. Faber, N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism. Thyroid 17(3), 237–241 (2007). https://doi.org/10.1089/thy.2006.0258
doi: 10.1089/thy.2006.0258
pubmed: 17381357
J. Faber, N. Wiinberg, S. Schifter, J. Mehlsen, Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur. J. Endocrinol. 145(4), 391–396 (2001). https://doi.org/10.1530/eje.0.1450391
doi: 10.1530/eje.0.1450391
pubmed: 11580994
I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344(7), 501–509 (2001). https://doi.org/10.1056/nejm200102153440707
doi: 10.1056/nejm200102153440707
pubmed: 11172193
J.A. Franklyn, K. Boelaert, Thyrotoxicosis. Lancet 379(9821), 1155–1166 (2012). https://doi.org/10.1016/s0140-6736(11)60782-4
doi: 10.1016/s0140-6736(11)60782-4
pubmed: 22394559
F.D. Hobbs, R.C. Davis, A.K. Roalfe, R. Hare, M.K. Davies, J.E. Kenkre, Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 324(7352), 1498 (2002). https://doi.org/10.1136/bmj.324.7352.1498
doi: 10.1136/bmj.324.7352.1498
pubmed: 12077039
pmcid: 116449
R.S. Gardner, F. Ozalp, A.J. Murday, S.D. Robb, T.A. McDonagh, N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 24(19), 1735–1743 (2003). https://doi.org/10.1016/j.ehj.2003.07.005
doi: 10.1016/j.ehj.2003.07.005
pubmed: 14522568
L.C. Costello-Boerrigter, G. Boerrigter, M.M. Redfield, R.J. Rodeheffer, L.H. Urban, D.W. Mahoney, S.J. Jacobsen, D.M. Heublein, J.C. Burnett Jr, Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J. Am. Coll. Cardiol. 47(2), 345–353 (2006). https://doi.org/10.1016/j.jacc.2005.09.025
doi: 10.1016/j.jacc.2005.09.025
pubmed: 16412859
pmcid: 2647136
M. Schultz, J. Faber, C. Kistorp, A. Jarlov, F. Pedersen, N. Wiinberg, P. Hildebrandt, N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin. Endocrinol. 60(1), 54–59 (2004). https://doi.org/10.1111/j.1365-2265.2004.01941.x
doi: 10.1111/j.1365-2265.2004.01941.x
M. Kohno, T. Horio, K. Yasunari, K. Yokokawa, M. Ikeda, N. Kurihara, Y. Nishizawa, H. Morii, T. Takeda, Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. Metabolism 42(8), 1059–1064 (1993). https://doi.org/10.1016/0026-0495(93)90023-h
doi: 10.1016/0026-0495(93)90023-h
pubmed: 8345811
T.S. Mir, R. Laux, H.H. Hellwege, B. Liedke, C. Heinze, H. von Buelow, S. Laer, J. Weil, Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 112(4), 896–899 (2003). https://doi.org/10.1542/peds.112.4.896
doi: 10.1542/peds.112.4.896
pubmed: 14523183
B. Biondi, E.A. Palmieri, G. Lombardi, S. Fazio, Effects of subclinical thyroid dysfunction on the heart. Ann. Intern. Med. 137(11), 904–914 (2002). https://doi.org/10.7326/0003-4819-137-11-200212030-00011
doi: 10.7326/0003-4819-137-11-200212030-00011
pubmed: 12458990
M. Tadic, S. Ilic, C. Cuspidi, T. Marjanovic, V. Celic, Subclinical hyperthyroidism impacts left ventricular deformation: 2D and 3D echocardiographic study. Scand. Cardiovasc. J. 49(2), 74–81 (2015). https://doi.org/10.3109/14017431.2015.1015441
doi: 10.3109/14017431.2015.1015441
pubmed: 25690254